FUJIFILM Wako Pure Chemical Corporation Installs New Equipment to Triple Production Capacity of GMP-Compliant Raw Materials for Pharmaceutical Manufacturing 

OSAKA, Japan, May 15, 2024 - FUJIFILM Wako Pure Chemical Corporation announces today that operations began utilizing new equipment that will triple¹ production capacity of GMP-compliant² raw materials for pharmaceutical manufacturing at its Osaka facility, located at 6-1 Takata-cho, Amagasaki City, Hyogo Prefecture, Japan.

The newly installed equipment will support the growing needs for raw materials such as stabilizers³ and buffers⁴ used in pharmaceutical manufacturing, as demand for biopharmaceuticals grows approximately 10% per annum⁵ driven by the increasing demand for antibody and gene therapeutics.

FUJIFILM Wako Pure Chemical Corporation’s suite of products and services for raw materials pharmaceutical manufacturing includes the “CertiPro” series of GMP-compliant raw materials, with a portfolio of various materials used in applications such as stabilizers and buffers as part of pharmaceutical manufacturing process. In addition, the Company offers the “Bioprocessing Solutions, which are tailored to concentrations and volumes used in a wide range of biopharmaceutical manufacturing processes. 

“With Fujifilm’s breadth of life science offerings from life sciences research tools to pharmaceutical manufacturing, we are supporting the advancement of a healthier and happier society. To support this, FUJIFILM Wako Pure Chemical will continue to develop and provide highly functional and high-quality products to meet the needs of society and customers, and contribute to the development of industry and academic research in a wide range of fields, including pharmaceuticals,” said Koichi Yoshida, the president and CEO of FUJIFILM Wako Pure Chemical.
 

1. 1 Compared to before the installation of production equipment.
2. 2 GMP stands for Good Manufacturing Practice, which is a standard for manufacturing and quality control of pharmaceutical drugs, and should be observed by manufacturers of pharmaceutical drug.
3. 3 Raw materials used for the purpose of ensuring the environment necessary for the stability of pharmaceuticals.
4. 4 Raw materials used for the purpose of ensuring an optimum pH environment necessary for the efficacy of a pharmaceuticals.
5. 5 Compound average growth rate from 2019 to 2026 (Source: Ministry of Economy, Trade and Industry of Japan, "Strengthening Bio CMO/CDMO").